In the Claims

Please substitute the following claims:

Claim 76 (Amended Three Times):

A method for delivering a polynucleotide encoding a protein to a vertebrate cell, said method comprising introducing into said vertebrate cell *in vitro* a recombinant entomopoxvirus vector, wherein said entomopoxvirus vector comprises said polynucleotide operably linked with a heterologous early poxvirus promoter sequence or a non-poxvirus promoter sequence, thereby delivering and expressing said polynucleotide encoding said protein in said vertebrate cell.

Claim 90 (Amended Four Times):

A recombinant entomopoxvirus vector comprising a polynucleotide encoding a protein operably linked with a non-poxvirus promoter sequence; and inverted terminal repeat sequences flanking said polynucleotide, wherein said non-poxvirus promoter sequence is activated by the cellular RNA polymerase of a vertebrate cell.

Claim 94 (Amended):

The vector according to claim 90, wherein said inverted terminal repeat sequences are derived from adeno-associated virus.

Claim 96 (Amended Three Times):

A recombinant entomopoxvirus vector comprising a polynucleotide encoding a protein operably linked with a CMV promoter sequence or herpes TK promoter sequence, wherein said CMV promoter sequence or herpes TK promoter sequence is activated by the cellular RNA polymerase of a vertebrate cell and is capable of driving expression of said polynucleotide.

Claim 98 (Amended):

A recombinant entomopoxvirus vector comprising a polynucleotide encoding a protein operably linked with a non-poxvirus promoter sequence, wherein said non-poxvirus promoter sequence is activated by the cellular RNA polymerase of a vertebrate cell, and wherein said polynucleotide encoding said protein is greater than about 10 kb in size.

Please cancel claims 86-87, 93, and 95, without prejudice.